Approved for use through
U.S. Patent and Trademark Office, U.S. DEI
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it confiant

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number			
Filing Date		2006-05-08	
First Named Inventor Alfon		s Eiterer	
Art Unit			
Examiner Name			
Attorney Docket Number		BEET-17	

	Remove						
Examiner Initial*			Kind Code <sup>1</sup>			Releva	Columns,Lines where nt Passages or Relevant s Appear
	1	5073687		1991-12-17	Inagawa et al.		
	2	5093548		1992-03-03	Schmidt-Hebbel		
	3	5103073		1992-04-07	Danilov et al.		
	4	5126532		1992-06-30	Inagawa et al.		
	5	6462306	B1	2002-10-08	Kitai et al.		
If you wis	h to a	dd additional U.S. Paten	t citatio	n information pl	lease click the Add button.		Add
U.S.PATENT APPLICATION PUBLICATIONS Remove							
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Name of Patentee of Applicant Re		Releva	Columns,Lines where nt Passages or Relevant s Appear
	1	20020056291	A1	2002-05-16	Schultz et al.		

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		2006-05-08
First Named Inventor Alfon		s Eiterer
Art Unit		
Examiner Name		
Attornou Docket Numb	or	DEET 17

	_	1						_			_
	2	20020134772	A1	2002-0	9-26	Troistski					
	3	20030006221	A1	2003-0	1-09	Hong et al.					
If you wis	h to a	dd additional U.S. Publi	ished Ap	plication	citatio	n information p	olease click the Ad	d buttor	. Add		
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>		Country Code <sup>2</sup> i Kind Code <sup>4</sup> Date Name of Patentee Applicant of cited Document		e or	where Re	or Relevant	T4		
	1	WO0018535	EP			2000-04-06	Wrba et al.				
	2	DE19960797	DE		C1	2001-09-13	Richter				
	3	DE10144008	DE	A1		2003-03-27	Granse et al.				
	4	DE10162379	DE		A1	2003-07-17	Granse				
If you wis	h to a	l dd additional Foreign P	atent Do	cument	citation	information pl	L lease click the Add	button	Add		
	NON-PATENT LITERATURE DOCUMENTS Remove								_		
Examiner Initials*	aminer Cite linclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the ite (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Ţ5				
	1	Patent Cooperation Tre	aty, Intern	ty, International Search Report, March 17, 2005, 4 pages, European Patent Office						e	

	Application Number		
NEODMATION DIOOLOGUDE	Filing Date		2006-05-08
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Alton	s Eiterer
Not for submission under 37 CFR 1.99)	Art Unit		
,	Examiner Name		
	Attorney Docket Numb	er	BEET-17

2	European Patent Office, International Preliminary Examination Report, Dated March 1, 2006, 12 pages	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature | Date Considered |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Tack Max Codes of USPTO Peace Documents at level USPTO, GOV or MECE 99104. 2 fater of this that issued the document by the two-lefter code (MPD Standard ST3). The Superior Standard ST30 are Superior Standard ST30 are should not superior ST30 a

# Application Number Flang Date 2006-05-08 First Number Number STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number 2006-05-08 First Number Num

### CERTIFICATION STATEMENT

Please see	37 CFR	1 97 a	nd 1 98 to	make the	appropriate	selection(s):

information disclosure statement. See 37 CFR 1.97(e)(1).

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 15(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the control of the control o

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/David H. Brinkman/	Date (YYYY-MM-DD)	2006-05-08
Name/Print	David H. Brinkman	Registration Number	40532

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant Affice, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.32.11.450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.2.11.450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.